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ABSTRACT Several 5-aminouracil derivatives that have previously been shown to inhibit Mycobacterium tuber-
culosis growth at concentrations of 5–40 µg/mL are demonstrated to act also as noncompetitive non-nucleoside 
inhibitors of HIV-1 reverse transcriptase without causing toxicity in vitro (МT-4 cells) and ex vivo (human 
tonsillar tissue).
KEYWORDS 5-(phenylamino)uracil derivatives, 5’-norcarbocyclic nucleoside analogs, HIV and Mycobacterium 
tuberculosis co-infection, dual action.
ABBREVIATIONS HIV, human immunodeficiency virus; TB, tuberculosis; WHO, World Health Organization; AIDS, 
acquired immunodeficiency syndrome; HIV NNRTIs, non-nucleoside inhibitors of HIV-1 reverse transcriptase.
INTRODUCTION
Currently, HIV infection and TB are believed to be the 
major causes of infectious deaths worldwide. According 
to the latest WHO statistics, 9 million people were new-
ly diagnosed with TB in 2013 and 1.5 million people died 
of TB (in 360,000 of these cases, TB was associated with 
HIV) [1]. In 2013, there were 35 million AIDS patients 
worldwide; 2.1 million cases of HIV infection were de-
tected in 2013, and 1.5 million people died of AIDS, 
with TB remaining the main cause of death with dual 
infection (66.5%) [2]. HIV-infected patients are at an 
increased risk of latent tuberculosis reactivation (50% 
with TB vs. 10% without), and HIV-infected TB pa-
tients face a high risk of death. HIV patients receiving 
anti-TB drugs during a standard 6-month regimen are 
at a higher risk of recurrence than TB patients receiv-
ing a longer course of therapy [3]. Thus, TB and HIV 
co-infection is a very serious issue requiring a search 
for dual-action drugs.
Recently, we demonstrated that some 5-arylamino-
uracil derivatives are capable of affecting active divi-
sion of Mycobacterium tuberculosis cells. Total inhibi-
tion of mycobacterium growth by compounds (2), (3), 
(6), (7), (10), (15)–(17), and (19) (Fig. 1) was observed 
at concentrations of 5–40 µg/mL, with compound (19) 
exhibiting a higher activity against the MS-115 strain 
with multiple-drug resistance (including five major 
first-line anti-TB drugs: isoniazid, rifampicin, strepto-
mycin, ethambutol, and pyrazinamide) than against the 
sensitive H37Rv laboratory strain [4].
This paper is devoted to the evaluation of 5-arylami-
nouracil derivatives as HIV NNRTIs and to a more de-
tailed investigation of the toxicity of these compounds.
EXPERIMENTAL
Compounds (1)–(20) were synthesized as previously 
described [4].
1-(4’-Hydroxy-2’-cyclopenten-1’-yl)-3-
benzyl-5-(phenylamino) uracil (21)
K2CO3 (36 mg, 0.26 mM) and BnBr (42 µL, 0.35 mM) 
were added to a compound (11) solution (50 mg, 
0.18 mM) in 5 mL of dimethylformamide (DMF). The 
reaction mixture was stirred at room temperature for 
24 h. The reaction progress was monitored by means of 
TLC. We removed the solvent in an oil pump vacuum, 
purified the residue using column chromatography on 
silica gel, and eluted it with the system CHCl
3
–CH
3
OH 
(98:2). In total, 43 mg of the product (21) (yield of 66%) 
was obtained as a yellowish powder. R
f
 = 0.32 (CHCl
3
–
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CH
3
OH, 98 : 2). 1H-NMR (CHCl
3
): 7.50–7.49 (2H, m, 
H
3
,H
5
-Bn), 7.32–7.23 (6H, m, H
2”
, H
3”, 
H
5”
, H
6”, 
H
2
,H
6
-Bn), 
6.95–6.93 (2H, m, H
5
, H
4
-Bn), 6.90–6.88 (1H, t, H
4”
), 6.20–
6.18 (1Н, m, H
2’
), 6.01 (1Н, s, NH), 5.84–5.82 (1H, m, H
3’
), 
5.61–5.58 (1H, m, H
1’
), 5.23–5.16 (2H, d, J = 13.70, CН
2
), 
4.84–4.83 (1H, m, H
4’
), 2.86–2.85 (1H, m, H
a5’
), 1.70–1.66 
(1H, m, H
b5’
). 13C-NMR (CHCl
3
): 160.80, 149.73 (C-4, 
C-2), 142.34 (C-4”), 139.24 (C-2’), 138.19 (C-4 Bn), 132.40 
(C-3’), 129.63 (C-3”, C-5”), 129.34 (C-3, C-5 Bn), 128.63 
(C-2”, C-6”), 127.91 (C-1”), 121.18 (C-1 Bn), 119.50 (C-5), 
117.19 (C-6), 113.11 (C-2, C-6, Bn), 74.99 (C-1’), 61.05 (C-
4’), 45.49 (C-5’), 39.94 (CH
2
).
1-(4’-Hydroxy-2’-cyclopenten-1’-yl)-3-benzyl-
5-(p-methylphenylamino) uracil(22)
The synthesis was carried out as for (21), with (12) 
used as a starting compound. Of the product (22), 35 
mg (yield of 68%) was obtained as a white-yellow pow-
der. R
f
= 0.43 (CHCl
3
–CH
3
OH, 98 : 2). 1H-NMR (CHCl
3
): 
7.50–7.48 (2H, m, H
3
,H
5
-Bn), 7.31–7.23 (4H, m, H
2
, H
4
, 
H
6
-Bn, H
5
), 7.06–7.04 (2H, m, H
3”
,H
5”
), 6.87–6.85 (2H, 
m, H
2”
, H
6”
)
, 
6.18–6.16 (1Н, m, H
2’
), 5.94 (1Н, s, NH), 
5.83–5.81 (1H, m, H
3’
), 5.58–5.56 (1H, m, H
1’
), 5.23–5.16 
(2H, d, J = 13.76, CН
2
), 4.84–4.82 (1H, m, H
4’
), 2.87–2.83 
(1H, m, H
a5’
), 2.26 (3Н, s, CН
3
), 1.69–1.65 (1H, m, H
b5’
). 
13C-NMR (CHCl
3
): 160.75, 149.66 (C-4, C-2), 139.57 (C-
4”), 139.14 (C-2’), 138.19 (C-4 Bn), 132.40 (C-3’), 130.14 
(C-3”, C-5”), 129.33 (C-3, C-5, Bn), 128.67 (C-2”, C-6”), 
127.88 (C-1”), 120.23 (C-1, Bn), 117.86 (C-2, C-6, Bn), 
117.66 (C-5), 114.39 (C-6), 75.02 (C-1’), 61.12 (C-4’), 45.45 
(C-5’), 39.94 (CH
2
), 20.76 (CН
3
).
Anti-HIV activity
Isolation of recombinant HIV-1 reverse transcriptase 
(p66/p51 heterodimer) and determination of its activ-
ity were performed as described earlier [5, 6]. The in-
hibition constant (K
i
), calculated according to Dixon’s 
method for noncompetitive inhibitors [7], was used as 
a quantitative measure of the inhibitory activity of 
the compounds. Nevirapine, a first-generation HIV 
NNRTI, was used as a control.
Cytotoxicity in vitro
We tested the compounds for potential cytotoxicity 
in the МT-4 cell line using an automatic cell counter 
(ChemoMetec). The number of live and dead cells was 
counted in the control cultures, and the cultures were 
treated with compound (6), (7), or (19). Compounds (6) 
and (7) were tested at concentrations of 0.136–33 µM 
(0.035–9 µg/mL), and compound (19) was tested at con-
centrations of 0.272–66 µM (0.119–28 µg/mL).
We discriminated live from dead cells by evaluating 
propidium iodide uptake according to the manufactur-
er’s instructions. We collected and analyzed data using 
the Nucleoview software (version 1.0,ChemoMetec).
Toxicity ex vivo
The cytotoxicity of compounds (6), (7), and (19) was de-
termined in human tonsillar tissues. A total of 27 tissue 
blocks were incubated with compound (19) (20 µg/mL) 
or with compound (6) or (7) (5 µg/mL) for each ex-
perimental point. Tissue blocks were cultured for 12 
days. Then, the cells were isolated from the control 
and treated and stained with combinations of fluores-
cence-labeled antibodies against CD3-QD605, CD4-
QD655, CD8-QD705, CD25-APC, CD38-PE, HLA-DR-
APC-Cy7, CXCR4-Brilliant violet 421, CCR5-PR-Cy5 
CD45RA-FITC, and CCR7-PE-Cy7 (Caltag Laborato-
ries; Biolegend). We determined the numbers of cells of 
different phenotypes in isolated suspensions using flow 
cytometry as previously described. The volume of an 
analyzed suspension was controlled by means of Tru-
count beads (Becton Dickinson); the number of counted 
cells was normalized to the weight of the tissue frag-
ments used for cell isolation.
RESULTS AND DISCUSSION
The structural similarity of compounds (1)–(20) to ura-
cil derivatives previously synthesized in our laboratory, 
together with their action as HIV NNRTIs [8, 9], sug-
gested that these compounds might have similar prop-
erties. Compounds (1)–(20) belong to two groups: (1)–
(10) are 5-arylaminouracil derivatives, while (11)–(20) 
(1)–(8): X = CH; (9)–(10): X = N
(1): R = H; (2): R = 3-Me; (3): R = 4-Me;
(4): R = 2,3-Me
2
; (5): R = 2,5-Me
2
;
(6): R = 4-nBu; (7): R = 4-nBuO;
(8): R = 4-PhO; (9): R = H; (10): R = 4-nBu
(11): R = H; (12): R = Me; (13): R = nBu;
(14): R = nBuO; (15): R = PhO
(16): R = H; (17): R = Me; (18): R = nBu;
(19): R = nBuO; (20): R = PhO
Fig.1
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contain one or two additional 4’-hydroxycyclopentene 
moieties and thus can be considered as 5’-norcarbocy-
clic analogs of 2’,3’-dideoxy-2’,3’-uridine. Despite the 
known structural similarity to nucleosides, the 5’-nor-
carbocyclic analogs are able to inhibit HIV reverse 
transcriptase through a non-competitive mechanism, 
binding at the so-called hydrophobic “non-nucleoside 
inhibitor binding center” [8, 9]. However, those among 
compounds (1)–(20) that inhibit the growth of M. tuber-
culosis did not possess the ability to inhibit HIV-1 re-
verse transcriptase (K
i
>> 200 µM). The only exception 
was compound (15) (K
i
 = 119 µM), which belongs to the 
class of 5’-norcarbocyclic analogs of uridine.
N3-benzyl derivatives (21) and (22) (Fig. 2) were 
synthesized to enhance the anti-HIV activity of com-
pounds of this class by increasing their hydrophobicity. 
These compounds were obtained in acceptable yields 
(61–69%) through a reaction of the initial carbocyclic 
analogs (11) and (12) with benzyl bromide in the pres-
ence of potassiumcarbonate. We confirmed the struc-
tures and purity of the synthesized compounds using 
1Н- and 13C-NMR-spectroscopy and TLC. The inhibito-
ry activity of the derivative (22) against HIV-1 reverse 
transcriptase appeared to be slightly higher than those 
of compound (21) (K
i
= 60 and>100 µM, respectively) 
and the initial compounds (11) and (12).
Previously, we had assessed the cytotoxicity of the 
synthesized compounds on Vero, A
549
, and Huh7 cell 
lines and demonstrated that they were nontoxic at con-
centrations of up to 50 µg/mL (CD
50 
>> 100 µM). The 
toxicity of compounds (6), (7), and (19), which exhibited 
the most pronounced anti-TB properties, was further 
investigated in vitro on the МT-4 cell line and ex vivo 
on human tonsillar tissue.
Neither the cytotoxic nor the cytostatic effect of the 
compounds in МT-4 cells were observed at concentra-
tions up to the maxima of 66 µM for (19) and 33 µM for 
(6) and (7).
Cytotoxicity assessment of the compounds (20 µg/mL 
for (19) and 5 µg/mL for (6) and (7)) on different cell 
types in the tissue system showed a lack of significant 
death rates of T cells (CD3+), B cells (CD3–), CD4+ and 
CD8+ T lymphocytes, and similarly for the CD4+ lym-
phocyte subgroups naive (CD45RA+/CCR7+), central 
memory cells (CD45RA–/CCR7+), effector memory 
cells CD45RA–/CCR7–), differentiated effector mem-
ory cells (Temra, CD45RA+/CCR7–), and activated 
CD4+ T-lymphocytes as well, with the last being identi-
fied as CD4+/CD25+, CD4+/CD38+T-cells, or CD4+/
HLA-DR+. In all of these groups, the number of cells in 
the control and treated tissues was the same.
Thus, despite the fact that the new 5-arylaminouracil 
derivatives showed no significant anti-HIV-activity, even 
the low activity of compounds (15) and (22) is indicative of 
their affinity for HIV-1 reverse transcriptase. The struc-
tural similarity of compounds of this type to many highly 
active antiviral agents of non-nucleoside nature which 
are used in HIV infection as components of complex, 
highly intensive antiretroviral therapy [10], in combina-
tion with their profound antituberculosis activity, makes 
them attractive targets for further modifications.  
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